To use magnesium sulphate for reducing fasciculations caused by etomidate during general anaesthesia.
Phase 2
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2023/12/060470
- Lead Sponsor
- Ashlesha Bankar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)Physical status ASA 1 and 2.
2)Patients scheduled for elective surgeries under general anaesthesia.
Exclusion Criteria
1)Refusal for participation.
2)Any known allergy or contraindication to the drug used.
3)Cerebrovascular disease.
4)Intracranial hypertension.
5)ASA 3 and 4.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 30 mg/kg of magnesium sulphate is expected to attenuate etomidate induced myoclonus.Timepoint: T0-pre-operative. <br/ ><br>T1-1st reading in operation theatre. <br/ ><br>T2-after magnesium sulphate(immediately). <br/ ><br>T3-after etomidate. <br/ ><br>T4-immediately after extubation. <br/ ><br>
- Secondary Outcome Measures
Name Time Method incidence of hypotension,bradycardia,post-op nausea and vomiting.Timepoint: T0-pre-operative. <br/ ><br>T1-1st reading in operation theatre. <br/ ><br>T2-after magnesium sulphate(immediately). <br/ ><br>T3-after etomidate. <br/ ><br>T4-immediately after extubation. <br/ ><br>